Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
NYU Langone Health
Age
Any age
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Any one or more of the following characteristics will qualify patient with T2/T3 prostate cancer for eligibility to current study:
Biopsy proven prostate cancer with Gleason score \> 7
Pathologic staging TXN1 (on MRI or CT)
Prostate-specific antigen (PSA) \> 10 ng/ml done within a month prior to study entry (the day of first hormonal ablation) and \> 10 days after prostate biopsy.
In addition patients must also have:
Performance status \< 2
Hemoglobin \> 11 grams per deciliter (g/dL), White blood cell (WBC) \> 4000 and platelet count \> 100.000/l
No evidence of other synchronous primary. Prior malignancies does not exclude if the patient is disease free \> 5 years.
Prior or concurrent basal cell or non-invasive squamous carcinoma of the skin is eligible and
Received hormone therapy with any of the following combination for less than 3 months
Lupron / Flutamide
Zoladex/ Flutamide
Lupron/ Casodex
Zoladex/ Casodex
You may not be if
Clinical stage T1N0, PSA \< 10, and Gleason score less than 7.
Evidence of distant metastasis
Previous surgery for prostate cancer (radical prostatectomy).
Current treatment with ketoconazole, cimetidine or hormone therapy for more than 3 months prior to inclusion in the protocol for prostate cancer
Major medical or psychiatric illness, which in the investigator's opinion may prevent completion of the study and interfere with follow up.
Bilirubin \> 1.5
Prior chemotherapy is not allowed
Clareo Health | Safety Study of Combination of Hormone Therapy, Paclitaxel and Radiation Therapy to Treat Prostate Cancer
